Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recu… (NCT07398170) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas: Proof-of-concept Study
France15 participantsStarted 2026-03
Plain-language summary
The goal of the clinical trial is to assess the presence of circulating tumor cells (CTCs) in the blood and/or cerebrospinal fluid (CSF) of patients with aggressive recurrent meningiomas.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Over 18 years of age
* Operated on for a grade 2 or 3 meningioma at Montpellier University Hospital between 2015 and 2024
* Tumour expressing SSTR2A on the initial surgical specimen
* Clinical and/or radiological recurrence as determined by MRI imaging (progression of a residual lesion OR appearance of a new lesion consistent with a meningioma at the surgical site or elsewhere)
Exclusion Criteria:
* Other active ongoing cancer
* Contraindications to lumbar puncture:
* Intracranial hypertension with meningioma exerting a mass effect and obstruction of the cerebrospinal fluid (CSF) pathway/risk of trans-tentorial or amygdalar herniation
* Blood clotting disorder with risk of haematoma at the puncture site (anticoagulant treatment at therapeutic dose or antiplatelet therapy, thrombocytopenia or thrombopathy)
* Infection at the puncture site
* Pregnant or breastfeeding women (Article L.1121-5 of the French Public Health Code)
* Persons deprived of their liberty by judicial or administrative decision (Article L.1121-6 of the French Public Health Code)
* Persons who are subject to legal protection measures or who are unable to express their consent (guardianship, curatorship, judicial protection; Article L.1121-8 of the French Public Health Code)
* Not affiliated with a social security scheme or beneficiary of such a scheme (Article L.1121-8-1 of the French Public Health Code)
* Persons participating in another study that includes an ongoing exclusion perio…
What they're measuring
1
Detection rate of circulating tumour cells (CTC) in blood
Timeframe: Before treatment of meningioma recurrence and at the end of meningioma recurrence treatment on Day 90 (± 15 days) in case of radiotherapy, or on Day 1 post-surgery in case of surgery
2
Detection rate of circulating tumour cells (CTC) in cerebrospinal fluid
Timeframe: Before treatment of meningioma recurrence